Moderators and speakers of the 8th AMR Conference 2024
Aanika Dalal
Co-Director, Alliance for Reducing Microbial Resistance (ARMoR)
Adrian Egli
Director, Institute of Medical Microbiology, University of Zurich
Alan Donnelly
Chair and Founder, The G20&G7 Health and Development Partnership
Alessandra Martini
Policy Officer, European Commission, DG Research and Innovation
Alexander Belcredi
Managing Director, BioNTech R&D (Austria) GmbH
Alexandra Cameron
Senior Expert, Unit Head A.I. Impact Initiatives and Research Coordination, AMR Division, World Health Organization
Baris Ata Borsa
Co-founder and CTO, Theralia AB
Betsy Wonderly Trainor
Alliance Director Diagnostics, CARB-X
Brenda Waning
Chief, STOP TB Global Drug Facility
Cary Adams
CEO, Union for International Cancer Control (UICC)
Caterina Bissantz
Expert Scientist, F. Hoffmann-La Roche
Christoph Dehio
Full Professor of Molecular Microbiology, Director of National Centre of Competence in Research (NCCR) “AntiResist”
Christopher Darlow
NIHR Academic Clinical Lecturer, University of Liverpool
Claudia Zampaloni
Senior Principal Scientist, Antibiotics Discovery, F. Hoffmann-La Roche Ltd
Clive Mason
Programme Director AMR, LifeArc
Coen van Hasselt
Associate Professor, Leiden University
Damiano de Felice
Director of Development and External Engagement, CARB-X
David Paterson
Professor ADVANCE-ID, National University of Singapore
Deepali Patel
Director of international policy, AMR Action Fund
Dennis M. Dixon
Chief of the Bacteriology and Mycology Branch, NIAID, NIH
Dionysios Neofytos
Attending Physician, University Hospital of Geneva
Douglas Häggström
Manager INCATE, University of Basel
Ed Buurman
Alliance Director CARB-X
Florence Séjourné
CEO, Aurobac Therapeutics & Treasurer, BEAM Alliance
Fuad Mirzayev
Team Lead, TB treatment team, World Health Organization
Gail Hayward
Associate Professor, Nuffield Department of Primary Care Health Sciences, University of Oxford
Gemma Johnson
Scientific Director, OLM Diagnostics Ltd
Glenn E. Dale
Chief Development Officer, BioVersys AG
Hee-Jong (Jason) Hwang
CEO, A&J Science
Hoon Sang Lee
Chief Strategy Officer, RIGHT Foundation
Ian Morrissey
Founder & Consultant, Antimicrobial Focus Ltd.
Jean-Baptiste Perrin
Policy Officer, European Commission - DG HERA
Jennifer Cohn
Director, Global Access at Global Antibiotic R&D Partnership (GARDP)
Jennifer Quinn
Global Head of Value and Access, Debiopharm International SA
Jens Hellwage
Managing Director, InfectoGnostics Research Campus Jena
Johan Wikstrom
CEO, Tolka AI Inc.
John J. S. Cadwell
President and CEO, FiberCell Systems Inc.
Jonathan Pearce
CEO, Antibiotic Research UK
Judith Moore
Head of Healthcare Initiatives, World Economic Forum
Kenneth Bradley
Global Head, Infectious Disease Discovery, Roche Pharma Research & Early Development (pRED)
Kevin Outterson
Austin B Fletcher Professor, Boston University, and Executive Director & Principal Investigator, CARB-X
Lara Urban
Principal Investigator, Helmholtz AI
Laura Plant
Head of External Affairs, International Vaccine Institute
Lothar H. Wieler
Chair, Digital Global Public Health, Hasso-Plattner-Institute
Lucas Boeck
Consultant Pulmonary Medicine, University Hospital Basel
Maarten J Postma
Chair, Global Health Economics, University Medical Center Groningen
Magda Rosenmöller
Associate Professor, IESE Business School
Mai Hoang
Senior Scientist, Dynamic42 GmbH
Marc Creus
CEO, TaBriX
Marc Gitzinger
CEO, BioVersys AG & President, BEAM Alliance
Marc Lemonnier
CEO, Antabio SAS
Maria Larsson Ortino
Senior Global ESG Manager, Legal & General Investment Management Ltd
Marianne Holm
Senior Research Scientist, Infectious Diseases, Novo Nordisk Foundation
Marie Petit
Partner, Villiger Valuation
Mark Albrecht
Chief, Antimicrobials Branch ASPR/BARDA
Mark Jones
Head of Development, Basilea Pharmaceutica International Ltd | BEAM Alliance - Board Member | Swiss Round Table for Antibiotics - Board Member
Markus Zeitlinger
Professor, Specialist for Internal Medicine and Clinical Pharmacology, Medical University of Vienna
Martin Everett
CSO, Aurobac Therapeutics
Matti Jalasvuori
CEO, PrecisionPhage Ltd.
Maximiliano G. Gutierrez
Principal Group Leader, Francis Crick Institute
Mercedes Gonzalez Moreno
Manager, INCATE
Michael Anderson
CEO, MedAccess
Michele Cecchini
Head of Public Health, Organisation for Economic Co-operation and Development (OECD)
Milovan Stankov-Pugès
CEO, NG Biotech
Mirfin Mpundu
Director, ReAct Africa
Muna Abu Sin
Epidemiologist, Robert Koch Institute
Nelly Badalato
R&D Department manager, GenoScreen
Nicolas Tesse
CSO, Septeos
Nina Khanna
Leading Senior Physician, University Hospital Basel
Olivier Menzel
Senior Health Advisor, Swiss Agency for Development and Cooperation (SDC), Federal Department of Foreign Affairs
Oxana Rucsineanu
Executive Director, Moldova National Association of Tuberculosis Patients
Patricia Martin
COO, LimmaTech Biologics AG
Pierre Dubois
Professor of Economics, Toulouse School of Economics
Pratik Bhatnagar
Global Public Health Director, IQVIA
Radu Botgros
Senior Scientific Officer, European Medicines Agency
Rafael Cantón
Head of Clinical Microbiology Department, Hospital Universitario Ramón y Cajal
Ralf Sudbrak
Interim Secretariat Lead, Global AMR R&D Hub
Ramanan Laxminarayan
President, One Health Trust
Remko van Leeuwen
CEO, SurvivX
Robert Macsics
CEO and Co-founder, smartbax GmbH
Shawna McCallin
Group Leader of Phage Therapy & Research, Balgrist University Hospital
Simon Gottwalt
Project Lead, Swiss antibiotic resistance strategy in human medicine, Swiss Federal Office of Public Health
Sophie Cooper
Senior scientific adviser Science Policy and Research Programme, National Institute for Health and Care Excellence, UK
Soumya Palliyil
CEO & Co-Founder, Brigid Biologics
Stuart Hannah
CEO, Microplate Dx Ltd
Surbhi Malhotra-Kumar
Head, Laboratory of Medical Microbiology, University of Antwerp
Susana Tomásio
Senior Application Scientist, Collaborative Drug Discovery
Thilo Köhler
Senior lecturer, University of Geneva, Department of Microbiology and Molecular Medicine
Thomas Van Boeckel
Assistant Professor, ETH Zurich
Till Bachmann
Deputy Head of Infection Medicine & Personal Chair of Molecular Diagnostics and Infection, University of Edinburgh
Toby Leslie
Global Technical Lead, Fleming Fund / Mott MacDonald
Ulrich Granzer
CEO, Granzer Regulatory Consulting & Services
Ursula Theuretzbacher
Founder, Center for Anti-Infective Agents
Valeria Gigante
Team Lead AMR Division, World Health Organization
Wolfgang Philipp
Acting Deputy Head HERA, European Commission
Yann Ferrisse
Director, Business Development & Partner Engagement, Global Access at Global Antibiotic R&D Partnership (GARDP)
Yves Briers
CEO, Obulytix
Zaki Sellam
CEO, Landmark BioVentures AG
Zoë Molyneux
Policy Lead, Wellcome Trust